• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

A Controversial Pick of the Year for 2018

Nothing breeds future investment success like buying in the face of negative headlines.
By PAUL PRICE
Jan 06, 2018 | 12:00 PM EST
Stocks quotes in this article: LL, MCK

Nothing breeds future investment success like buying in the face of negative headlines. Few venues have as much negative shock value as a scathing profile on the 60 Minutes TV show.

Bad publicity on Lumber Liquidators (LL) in March 2015 nearly killed the company. Its shares plunged from $70 to $10 over about a nine-month period before finally stabilizing. Bargain hunters with patience, though, got rewarded as LL gradually worked its way back to over $41.

That company's long-term survival seemed in doubt when the 60 Minutes report aired. A few hedge funds, with disclosed short positions, were very publicly proclaiming that LL was going to zero.

A more recent 60 Minutes feature segment concerned itself with the FDA's opioid addiction crisis investigation. CBS focused on drug distributor McKesson (MCK) as a contributing culprit. In the wake of that broadcast, MCK shares, which peaked north of $243 back in 2015, briefly dropped to less than $134.

The problems described were never life-threatening to a blue-chip, large-cap firm like McKesson. As things turned out, MCK was able to pay a very manageable fine, make some adjustments and continue on its way.

60 Minutes, and some of its viewers, was outraged, leading to a second on-air blasting in December. MCK remains well below its old highs yet figures to post all-time record earnings per share in the fiscal years ending Mar. 31, 2018 and Mar. 31, 2019.

I smell an opportunity as the bad publicity fades away and fundamentals come back into play. McKesson gets Value Line's highest rank for financial strength. It is on pace to do about $215 billion in current year revenues. Its dividend is raised regularly, earnings are quite predictable and the stock has outperformed most of the 1,700 companies contained in Value Line's main research universe.

How does McKesson look based on its operating numbers? Very good indeed. At its Dec. 31, 2017 closing quote of $155.95, MCK sells for just 12.1x next year's expected EPS of $12.91. That's very similar to the valuations present at the stock's six previous "best buying opportunities" of the past eight years (green-starred below).

McKesson's average P/E since 2010 has run about 15.5x. That was typically accompanied by a current yield of around 0.78%. The stock is substantially cheaper than average on both measures right now.

A simple regression to the mean valuation on FY 2018's projected earnings would justify a rebound to about $200. That goal is more than 28% above the recent price and it's far from an upper limit. MCK traded between $214 and $243 during both 2014 and 2015 when sales, earnings and dividends were well below today's levels.

Don't just take my word on this. Independent analysis from Morningstar sees it pretty much the same way. They rate MCK as a 4-star (out of 5) but while noting the firm's wide moat and low P/E. Morningstar calls McKesson's present day fair value as $210.

Standard & Poor's analyst Danny Yang has a hard-to-figure "Hold" ranking on MCK. What leads me to say that? S&P's computer-generated fair value score shows MCK in the highest quintile (most undervalued). It's fair value is pretty astonishing, coming in at $339.91 per share.

What's more, S&P apparently thinks MCK has bullish technicals and that it could more than double just by arriving at fair value. Yet the firm fails to assign it a Buy ranking.

Standard & Poor's fair value viewpoint is not crazy, although it might take a bit of time to achieve. Value Line sees MCK potentially reaching the same basic neighborhood, but by 2020 to 2022.

Option writers can participate in MCK's expected rebound by selling Jan. 2020 expiration date puts. The in-the-money $170 and $180 strikes provide excellent profit potential while still offering downside protection of 5.6% to 8.4%.

Maximum profit would be keeping 100% of all premium received. In these examples that would equal $2,720, or $3,285 per 100-share commitment.

I'm betting that McKesson will be a star in 2018 and beyond. Buy some shares, sell some puts or consider doing both.

This column originally appeared on Jan. 3 on Real Money Pro, our premium site for active traders and Wall Street professionals. Click here to get great columns like this even earlier in the trading day.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Price was long MCK shares, short MCK Jan. 2018 and Jan. 2019 puts.

TAGS: Investing | U.S. Equity | Healthcare | Options | Stocks

More from Healthcare

Emergent BioSolutions Turns Bearish, So Beware

Bruce Kamich
Mar 4, 2021 8:27 AM EST

A break in a key support level could precipitate further declines in the life sciences company's shares.

Centene Charts Remain Weak and Vulnerable

Bruce Kamich
Mar 3, 2021 1:35 PM EST

Let's review the charts and indicators.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Bruce Kamich
Mar 3, 2021 12:20 PM EST

Stand aside for now.

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login